MIAMI–(BUSINESS WIRE)–lt;a href="" target="_blank"gt;$MDCOlt;/agt; lt;a href="" target="_blank"gt;#cholesterollt;/agt;–The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study. These results were presented tod

Source link